Charles Schwab Investment Management Inc. Buys 10,717 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Charles Schwab Investment Management Inc. boosted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 3.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 361,805 shares of the company’s stock after purchasing an additional 10,717 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Vera Therapeutics were worth $15,992,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. Intech Investment Management LLC bought a new stake in Vera Therapeutics during the 3rd quarter valued at approximately $475,000. Jennison Associates LLC boosted its stake in Vera Therapeutics by 1.3% during the 3rd quarter. Jennison Associates LLC now owns 447,098 shares of the company’s stock valued at $19,762,000 after purchasing an additional 5,936 shares during the period. First Turn Management LLC boosted its stake in Vera Therapeutics by 53.3% during the 3rd quarter. First Turn Management LLC now owns 326,494 shares of the company’s stock valued at $14,431,000 after purchasing an additional 113,550 shares during the period. Victory Capital Management Inc. boosted its stake in Vera Therapeutics by 13.5% during the 3rd quarter. Victory Capital Management Inc. now owns 38,253 shares of the company’s stock valued at $1,691,000 after purchasing an additional 4,546 shares during the period. Finally, Chartwell Investment Partners LLC boosted its stake in Vera Therapeutics by 63.5% during the 3rd quarter. Chartwell Investment Partners LLC now owns 19,172 shares of the company’s stock valued at $847,000 after purchasing an additional 7,447 shares during the period. Institutional investors own 99.21% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 target price on shares of Vera Therapeutics in a research note on Tuesday, October 1st. Guggenheim upped their price target on Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Monday, October 28th. Wedbush upped their price target on Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a report on Friday, November 8th. JPMorgan Chase & Co. upped their price target on Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Finally, Evercore ISI raised Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $59.22.

Insider Transactions at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 15,625 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $37.50, for a total transaction of $585,937.50. Following the sale, the chief executive officer now directly owns 307,972 shares in the company, valued at $11,548,950. This represents a 4.83 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Beth C. Seidenberg sold 15,000 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $48.03, for a total value of $720,450.00. Following the sale, the director now owns 131,553 shares in the company, valued at approximately $6,318,490.59. This trade represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 89,927 shares of company stock valued at $3,800,796. Corporate insiders own 21.70% of the company’s stock.

Vera Therapeutics Trading Up 0.7 %

Shares of VERA opened at $48.46 on Friday. Vera Therapeutics, Inc. has a 1 year low of $13.09 and a 1 year high of $51.61. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock has a 50 day simple moving average of $44.61 and a 200-day simple moving average of $40.03. The stock has a market cap of $3.07 billion, a PE ratio of -18.57 and a beta of 1.08.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). On average, sell-side analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.